Spotlight On... Mayo Clinic, Kiyatec team up on personalized ovarian cancer care; Surmodics will add 100 jobs as part of an expansion in Ireland; Oventus prices IPO at $12 million; and more...

Cancer diagnostics player Kiyatec is joining forces with Mayo Clinic to combine their complementary technologies for ovarian cancer care. Mayo Clinic is enrolling for a trial to assess whether living tumor samples generated from patient-derived xenografts can determine which chemotherapy is most effective for individual patients. Meanwhile, Kiyatec uses its 3-D cell culture platform to generate patient-specific data to predict their response to particular drugs. The hope is the collaboration will allow more patients to receive personalized ovarian cancer treatment thanks to these response models. Release

> Surmodics will add 100 new jobs in Galway, Ireland over the next 5 years. Story

> Sleep disorder device maker Oventus prices its IPO on the Australian Securities Exchange at $12 million. Release

> The U.K.'s NHS will acquire 7 TomoTherapy Systems from Accuray ($ARAY). Release

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.